
Verona Pharma (VRNA) Earnings Dates & Reports
Verona Pharma (VRNA) Most Recent Earnings
Report Date
Period EndingQ2 2025
Est. EPS$0.06
Actual EPS$0.13
EarningsBeat
Verona Pharma (VRNA) Earnings
View the latest Verona Pharma (VRNA) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in Verona Pharma (VRNA)
Order type
Buy in
Order amount
Est. shares
0 shares
Verona Pharma (VRNA) Earnings per Share (EPS) History
Signup for full accessBrowse free
Verona Pharma (VRNA) Latest Earnings
The value each VRNA share was expected to gain vs. the value each share gained.
Verona Pharma (VRNA) reported its most recent earnings on for Q2 2025, posting earnings per share (EPS) of $0.13. This exceeded analysts' expectations of $0.06 by 116.67%, marking a Beat.
For comparison, Verona Pharma reported EPS of -$0.80 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of $0.20.
Verona Pharma (VRNA) Earnings History
Verona Pharma (VRNA) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the Verona Pharma’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
Verona Pharma (VRNA) Earnings FAQs
Verona Pharma (VRNA) last reported earnings on Aug 6, 2025 for Q2 2025, posting an EPS of $0.13, which Beat the estimate of $0.06 by 116.67%.
For Q2 2025, Verona Pharma (VRNA) reported an EPS of $0.13, exceeding analysts' estimate of $0.06 by 116.67%.
For Q2 2025, Verona Pharma (VRNA) Beat expectations with an actual EPS of $0.13 vs. an estimated EPS of $0.06.
Following the last earnings report on Aug 6, 2025, Verona Pharma (VRNA)'s stock price moved — from — to —.
The next Verona Pharma (VRNA) earnings call is scheduled for Dec. 26, 2025, where executives will discuss financial results and outlook.